Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
24321257
DOI
10.1016/j.urolonc.2013.09.011
PII: S1078-1439(13)00384-0
Knihovny.cz E-resources
- Keywords
- prognosis, renal cell carcinoma, sorafenib, sunitinib, survival,
- MeSH
- Cytokines therapeutic use MeSH
- Adult MeSH
- Phenylurea Compounds administration & dosage MeSH
- Indoles administration & dosage MeSH
- Carcinoma, Renal Cell drug therapy mortality secondary MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Survival Rate MeSH
- Kidney Neoplasms drug therapy mortality pathology MeSH
- Follow-Up Studies MeSH
- Niacinamide administration & dosage analogs & derivatives MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyrroles administration & dosage MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Sorafenib MeSH
- Neoplasm Staging MeSH
- Sunitinib MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cytokines MeSH
- Phenylurea Compounds MeSH
- Indoles MeSH
- Niacinamide MeSH
- Pyrroles MeSH
- Sorafenib MeSH
- Sunitinib MeSH
OBJECTIVES: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. MATERIALS AND METHODS: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. RESULTS: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs<1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI<1 year, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. We have also validated the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model in our cohort of patients. CONCLUSION: We demonstrate that the International Database Consortium prognostic model performs well for European patients treated with TKIs, including sunitinib or sorafenib, after progression on cytokines and suggest that a reduction from original 6 down to 4 parameters is possible.
Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic
Department of Oncology University Hospital of Motol Charles University Prague Czech Republic
Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic
References provided by Crossref.org
